Showing results (21-30 of 39) with videos related to
Sort By:
Pageof 4
Current Treatment Options in Oncology|March 13, 2024
Ovarian Suppression: Early Menopause and Late EffectsChiara Molinelli, Flavia Jacobs, Guilherme Nader-Marta, et al.Pathology Oncology Research : POR|June 26, 2020
Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell CarcinomaGuilherme Nader Marta, Pedro Isaacsson Velho, Renata R C Bonadio, et al.Journal of Cancer Research and Clinical Oncology|July 22, 2022
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysisDiogo Martins-Branco, Guilherme Nader-Marta, Ana Tecic Vuger, et al.Ecancermedicalscience|January 11, 2020
Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?Renata Colombo Bonadioa, Pedro Isaacsson Velho, Guilherme Nader Marta, et al.Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.Future Oncology (London, England)|June 13, 2022
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breastElisa Agostinetto, Guilherme Nader-Marta, Marianne Paesmans, et al.British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.Breast Cancer Research : BCR|June 13, 2025
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric studyKaren Van Baelen, Ha-Linh Nguyen, François Richard, et al.Breast (Edinburgh, Scotland)|June 27, 2026
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trialChiara Molinelli, Virginia Delucchi, Eva Blondeaux, et al.Journal for Immunotherapy of Cancer|December 6, 2023
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trialAlex De Caluwe, Emanuela Romano, Philip Poortmans, et al.Pageof 4